|
- Zenocutuzumab - Wikipedia
Zenocutuzumab, sold under the brand name Bizengri, is a humanized monoclonal antibody used for the treatment of non-small cell lung cancer or pancreatic cancer [1] It is a low-fucose humanized full-length immunoglobulin G1 bispecific HER2 - and HER3 -directed antibody
- FDA grants accelerated approval to zenocutuzumab-zbco
On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N V ) for adults with the following: advanced, unresectable, or
- Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
In the multinational eNRGy study, zenocutuzumab, a bispecific antibody against HER2 and HER3, showed durable antitumor activity in patients with NRG1 fusion–positive cancer
- Zenocutuzumab Uses, Side Effects Warnings - Drugs. com
Zenocutuzumab is used in adults to treat certain types of lung and pancreatic cancer that cannot be removed with surgery or has spread to other parts of the body (metastatic) Zenocutuzumab is given after other treatments did not work or stopped working
- FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers With NRG1 . . .
The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene fusion, based on a phase 2 clinical trial led by an MSK investigator
- Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy . . .
Zenocutuzumab, a HER2xHER3 bispecific antibody, reduces cell growth in NRG1-rearranged cancer cell lines and xenografts and induces durable clinical responses in patients with NRG1 fusion–positive tumors
- Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody . . .
Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2
- Bizengri Approved to Treat Some Lung, Pancreatic Cancers
Under the approval, zenocutuzumab can be used to treat people with pancreatic or non-small cell lung cancer (NSCLC) whose tumors have an NRG1 fusion and whose disease has gotten worse despite standard treatments
|
|
|